49 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
biotechnology industry and society at large.
EXECUTIVE AND DIRECTOR COMPENSATION
Executive Officers
Certain information regarding our executive
424B5
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Prospectus supplement for primary offering
4:53pm
, who are not suitable candidates for standard intensive chemotherapy.
At the 62nd American Society of Hematology Annual Meeting and Exposition held
8-K
EX-99.1
g9yhxlppv9yha7c9mru
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.2
vjzh pyk9r167t91n
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.2
c4o hwsty7
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
jai1laltjk5cxo hss
12 Dec 22
Regulation FD Disclosure
7:48am
425
vj81t
5 Jul 22
Business combination disclosure
7:14am
8-K
EX-2.1
i7ycdtust9wo7kno7sh2
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am